
News|Articles|July 1, 2004
TNF inhibitor use associated with granulomatous infectious disease; infliximab poses greatest risk
Tumor necrosis factor (TNF) antagonists increase the risk of granulomatous infectious disease, including tuberculosis, according to a study-the largest of its kind to date-published in the journal Clinical Infectious Diseases. The risk of infection was 3.25-fold greater among patients who received infliximab (Remicade, Centocor) than among those who received etanercept (Enbrel, Wyeth/Amgen), the study found.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers
2
Transforming care through social determinants of health
3
The MASLD-breast cancer connection
4
FDA approves Lumvoa, first TED therapy labeled for both active and chronic disease
5






























